General Pharmaceutics - The new physical pharmacy

Journal of Pharmaceutical Sciences

Volumn 92, Issue 7, 2003, Pages 1331-1342

  Fiese, E F ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Absorption; Crystallinity; Particle size; Polymorph; Profiles; Solubility; Stability

Indexed keywords

DRUG;

ABSORPTION; BIOAVAILABILITY; CRYSTALLIZATION; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM; PARTICLE SIZE; PHARMACY; PROTEIN STABILITY; SHORT SURVEY; SOLUBILITY;

EID: 0038421707     PISSN: 00223549     EISSN: None     Source Type: Journal    
DOI: 10.1002/jps.10366     Document Type: Short Survey

References (49)

1. Busse LW. 1950. Physical Pharmacy. Am J Pharm Ed 14:355-358.
2. Reynolds DW, Facchine KL, Mullaney JF, Alsante KM, Hatajik TD, Motto MG. 2002. Available guidance and best practices for conducting forced degradation studies. Pharm Technol Feb: 48-54.
3. Kerns EH. 2001. High throughput physicochemical profiling for drug discovery. J Pharm Sci 90:1838-1858.
4. Morris KR, et al. 1994. An integrated approach to the selection of optimal salt form for a new drug candidate. Int J Pharm 105:209-217.
5. PoJymorphs. 1999. In: Byrn SR, Pfeiffer RR, Stowell JG, editors. Solid-state chemistry of drugs, 2nd Ed. West Lafayette, IN: SSCI, p 143-231.
6. Brittain HG, Byrn SR. 1999. Structural aspects of polymorphism. In: Brittain HG, editor. Polymorphism in pharmaceutical solids. New York: Marcel Dekker, p 73-124.
7. Nichols G, Frampton CS. 1998. Physicochemical characterization of the orthorhombic polymorph of paracetamol crystallized from solution. J Pharm Sci 87:684-693.
8. Joiris E, DiMartino P, Berneron C, Guyot-Hermann A-M, Guyot J-C. 1998. Compression behavior of orthorhombic paracetamol. Pharm Res 15:1122-1130.
9. Amorphous solids. 1999. In: Byrn SR, Pfeiffer RR, Stowell JG, editors. Solid-state chemistry of drugs, 2nd Ed. West Lafayette, IN: SSCI Inc., p 249-258.
10. Hancock BC, Parks M. 2000. What is the true solubility advantage for amorphous pharmaceuticals? Pharm Res 17:397-404.
11. Hancock BC, Zografi G. 1997. Characteristics and significance of the amorphous state in pharmaceutical systems. J Pharm Sci 86:1-12.
12. Guo Y, Byrn SR, Zografi G. 2000. Physical characteristics and chemical degradation of amorphous quinapril hydrochloride. J Pharm Sci 89:128-143.
13. Xu W. 1997. Ph.D.Thesis Purdue University, West Lafayette, IN.
14. Hintz RJ, Johnson KC. 1989. The effect of particle size distribution ondissolution rate and oral absorption. Int J Pharm 51:9-17.
15. Lu ATK, Frisella ME, Johnson KC. 1993. Dissolution modeling: Factors affecting the dissolution rates of polydisperse powders. Pharm Res 10:1308-1314.
16. Johnson KC, Swindell AC. 1996. Guidance in the setting of drug particle size specifications to minimize variability in absorption. Pharm Res 13:1795-1798.
17. Hiestand EN, Smith DP. 1984. Indices of tableting performance. Powder Technol 38:145-159.
18. Hiestand EN. 1985. Dispersion forces and plastic deformation in tablet bond. J Pharm Sci 74:768-770.
19. Hiestand EN. 1989. The basis for practical applications of the tableting indices. Pharm Tech 54-66.
20. Hancock BC, Carlson GT, Ladipo D, Langdon BA, Mullarney M. 2001. The powder flow and compact mechanical properties of two recently developed matrix-forming polymers. J Pharm Pharmacol 53:1193-1199.
21. Albert A, Serjeant EP. 1984. In: The determination of ionization constants, 3rd Ed. New York: Chapman and Hall, p 14-124.
22. Streng WH. 2001. Equilibrium constants. In: Characterization of compounds in solution: Theory and practice. New York: Kluwer Academic/Plenum Publishers, p 87-97.
23. Jia Z, Ramstad T, Zhong M. 2001. Medium-throughput pKa screening of pharmaceuticals by pressure-assisted capillary electrophoresis. Electrophoresis 22:1112-1118.
24. Lipinski CA. 2000. Drug - like properties and the causes of poor solubility and poor permeability. J Pharm Tox Methods 44:235-249.
25. Hildebrand JH, Scott RL. 1950. The ideal solution. In: The solubility of nonelectrolytes, 3rd Ed. New York, NY: Reinhold Publishing, p 16-28.
26. Yalkowsky SH, Valvani SC. 1980. Solubility and partitioning I: Solubility of nonelectrolytes in water. J Pharm Sci 69:912-922.
27. Rajewski RA, Stella VJ. 1996. Pharmaceutical applications. 2. In vivo drug delivery. J Pharm Sci 85:1142-1168.
28. Hernell O, Staggers JE, Carey MC. 1990. Physical-chemical behavior of dietary lipids during intestinal digestion and absorption. 1. Phase behavior and aggregation states of model lipid systems patterned after aqueous duodenal contents of healthy adult human beings. Biochemistry 29:2028-2040.
29. Staggers JE, Hernell O, Stafford RJ, Carey MC. 1990. Physical-chemical behavior of dietary and biliary lipids during intestinal digestion and absorption. 2. Phase analysis and aggregation states of luminal lipids during duodenal fat digestion in healthy adult human beings. Biochemistry 29:2041-2056.
30. Curatolo W. 1994. Intestinal fluids and permeability enhancers. Proceed Int Symp Controlled Release Bioact Mater 21:575-576.
31. Reaction kinetics. 1999. In: Byrn SR, Pfeiffer RR, Stowell JG, editors. Solid-state chemistry of drugs, 2nd Ed. West Lafayette, IN: SSCI, p 443-460.
32. Solution stability. 2001. In: Streng WH, editor. Characterization of compounds in solution: Theory and practice. New York, NY: Kluwer Academic/ Plenum, p 87-97.
33. Wirth DD, Baertschi SW, Johnson RA, Maple SR, Miller MS, Hallenbeck DK, Gregg SM. 1998. Maillard reaction of lactose and fluoxetine hydrochloride, a secondary amine. J Pharm Sci 87:31-39.
34. Minick DJ, Frenz JH, Patrick MA, Brent DA. 1988. zA comprehensive method for determining hydrophobicity constants by reverse-phase high-performance chromatography. J Med Chem 31:1923-1933.
35. Boudeville P, Bona M, Burgot J-L. 1996. Correlations between n-octanol/water Partition coefficients and RP-HPLC capacity factors of 1, 2-dithiole-3-thiones and 1,2-dithiol-3-ones. J Pharm Sci 85:990-998.
36. Clarke FH, Cahoon NM. 1987. Ionization constants by curve fitting: Determination of partition and distribution coefficients of acids and bases and their ions. J Pharm Sci 76:611-620.
37. Dressman JB, Amidon GL, Fleisher D. 1985. Absorption potential: Estimating the fraction absorbed for orally administered compounds. J Pharm Sci 74:588-589.
38. Sanghvi T, Ni N, Yalkowsky SH. 2001. A simple modified absorption potential. Pharm Res 18:1794-1796.
39. Curatolo WJ. 1998. Physical chemical properties of oral drug candidates in the discovery and exploratory development settings. Pharm Sci Technol Today 1:387-393.
40. Fagerholm U, Johansson M, Lennerns H. 1996. Comparison between permeability coefficients in rat and human jejunum. Pharm Res 13:1336-1341.
41. Ho N, Park PN, Higuchi WI. 1983. Advancing quantitative and mechanistic approaches in interfacing gastrointestinal drug absorption studies in animals and humans. In: Crouthamel W, Sarapu A, editors. Animal models for oral drug delivery in man. Washington, DC: American Pharmaceutical Association, p 27-106.
42. Sutton SC, Rinaldi MTS, Vukovinsky KE. 2001. Comparison of the gravimetric, phenol red and 14C-PEG-3350 methods to determine water absorption in the rat single pass intestinal perfusion model. AAPS Pharm Sci 3(3): article 25.
43. Sutton SC, Rinaldi MTS, McCarthy JM, Vukovinsky KE. 2002. A statistical method for the determination of absorption rate constant estimated using the rat single pass intestinal perfusion model and multiple linear regression. J Pharm Sci 91:1046-1053.
44. Artursson P. 1991. Cell cultures as models for drug absorption across the intestinal mucosa. Crit Rev Ther Drug Carrier Syst 8:305-330.
45. Quaroni A, Hochman J. 1996. Development of intestinal cell culture models for drug transport and metabolism studies. Adv Drug Dev Rev 22:67-84.
46. Yee S. 1997. In vitro permeability across Caco-2 cells (colonic) can predict in vivo (small intestinal) absorption in man - Fact or myth. Pharm Res 14:763-766.
47. Amidon GL, Lennernäs H, Shah VP, Crison JR. 1995. A theoretical basis for a biopharmaceutic drug classification: The correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 12:413-419.
48. FDA. 2000. Guidance for industry: Waiver of in vivo bioavailability and bioequivalence studies for immediate release solid oral dosage forms containing certain active moieties/active ingredients base on a biopharmaceutics classification system. Rockville, MD: U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research.
49. Yu LX, Amidon GL, Polli JE, Zhao H, Mehta MU, Conner DP, Shah VP, Lesko LJ, Chen M-L, Lee VHL, Hussain AS. 2002. Biopharmaceutics classification system: The scientific basis for biowaiver extensions. Pharm Res 19:921-925.